pioglitazone has been researched along with Kidney Diseases in 31 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study investigated the role of N-methyl-D-aspartate (NMDA) receptors in pioglitazone-mediated protection against renal ischemia reperfusion injury (IRI) in rats." | 7.83 | Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats. ( Bedi, PM; Singh, AP; Singh, N, 2016) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 7.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| " Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence." | 7.75 | The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. ( Deleuze, S; Fogo, AB; Ma, LJ; Potthoff, SA; Yang, HC; Zuo, Y, 2009) |
| "Pioglitazone has been demonstrated to exert anti-fibrotic and renoprotective effects." | 5.51 | Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. ( Chen, Y; Qu, W; Song, X; Sun, D; Sun, L; Xu, T; Yao, L; Yuan, Q, 2019) |
| "The goal of the meta-analysis was to evaluate the effect of pioglitazone on the primary and secondary prevention of cardiovascular diseases (CVDs) and renal adverse events in patients with or at high risk of type 2 diabetes mellitus (T2DM)." | 5.05 | Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. ( Huang, Y; Ji, X; Shen, L; Wang, X; Wang, Y; Zhou, Y, 2020) |
| "Adriamycin-exposed rats developed proteinuria, an increased cortical HPSE and decreased heparan sulfate (HS) expression, which was ameliorated by treatment with pioglitazone." | 4.31 | Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria. ( Buijsers, B; de Graaf, M; Garsen, M; Gockeln, L; Hillebrands, JL; Kamps, JAAM; Krenning, G; Lamb, HJ; Maciej-Hulme, ML; Nijenhuis, T; Rabelink, TJ; Sol, M; Sonneveld, R; van den Born, J; van der Meer, RW; van der Vlag, J; van Kuppevelt, TH; van Raalte, DH, 2023) |
| "The present study investigated the role of N-methyl-D-aspartate (NMDA) receptors in pioglitazone-mediated protection against renal ischemia reperfusion injury (IRI) in rats." | 3.83 | Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats. ( Bedi, PM; Singh, AP; Singh, N, 2016) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 3.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| " Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence." | 3.75 | The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. ( Deleuze, S; Fogo, AB; Ma, LJ; Potthoff, SA; Yang, HC; Zuo, Y, 2009) |
| "Pioglitazone was well tolerated in patients with varying degrees of renal impairment." | 2.71 | The pharmacokinetics of pioglitazone in patients with impaired renal function. ( Budde, K; Eckland, D; Fritsche, L; Neumayer, HH; Stompôr, T; Sulowicz, W, 2003) |
| "Though gout is more prevalent in men than women, it remains unclear whether gender influences risk factors for incident gout." | 2.61 | Gender-specific risk factors for gout: a systematic review of cohort studies. ( Belcher, J; Evans, PL; Hay, CA; Mallen, CD; Prior, JA; Roddy, E, 2019) |
| "Autosomal dominant polycystic kidney disease (ADPKD) is the most common of the monogenic disorders and is characterized by bilateral renal cysts; cysts in other organs including liver, pancreas, spleen, testis and ovary; vascular abnormalities including intracranial aneurysms and subarachnoid hemorrhage; and cardiac disorders such as left ventricular hypertrophy (LVH), mitral valve regurgitation, mitral valve prolapse and aortic regurgitation." | 2.48 | PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders. ( Nagao, S; Yamaguchi, T, 2012) |
| "Pioglitazone was given orally [10mg/kg/day] for 28 days and adiponectin intraperitoneally [2." | 1.56 | Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats. ( Abdul Sattar, M; Afzal, S; Eseyin, OA; Johns, EJ, 2020) |
| " This finding could be of great importance for the wider use of aminoglycosides, with therapy that would reduce the occurrence of serious adverse effects, such as nephrotoxicity and acute renal failure." | 1.51 | Pioglitazone attenuates kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats. ( Divac, N; Jovanović, GB; Kekić, D; Medić, B; Prostran, M; Radenković, M; Rovčanin, B; Škodrić, SR; Stojanović, M; Stojanović, R; Vujović, KS, 2019) |
| "Pioglitazone has been demonstrated to exert anti-fibrotic and renoprotective effects." | 1.51 | Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. ( Chen, Y; Qu, W; Song, X; Sun, D; Sun, L; Xu, T; Yao, L; Yuan, Q, 2019) |
| "Pioglitazone treatment abrogated renal oxidative stress (decreased reduced glutathione and catalase activity and increased malondialdehyde), elevated serum cytokine (interleukin-6, interleukin-10, tumor necrosis factor-alpha and transforming growth factor-beta1) and Fas induced by MTX." | 1.42 | Pioglitazone ameliorates methotrexate-induced renal endothelial dysfunction via amending detrimental changes in some antioxidant parameters, systemic cytokines and Fas production. ( El-Gowelli, HM; El-Gowilly, SM; Helmy, MM, 2015) |
| "Pioglitazone treatment with low-dose cyclosporine has synergistic protective effects for cardiac allografts and recipient kidneys, leading to improvement of graft survival with a minimal cyclosporine-induced nephrotoxicity." | 1.35 | Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation. ( Chen, Z; Hasegawa, T; Okada, K; Okita, Y; Tanaka, Y, 2009) |
| "Pioglitazone is an agonist of PPARgamma, capable of reducing chronic inflammation." | 1.33 | Pioglitazone limits cyclosporine nephrotoxicity in rats. ( Câmara, NO; Campaholle, G; Cenedeze, MA; de Paula Antunes Teixeira, V; dos Reis, MA; Pacheco-Silva, A; Pereira, MG, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 19 (61.29) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Garsen, M | 1 |
| Buijsers, B | 1 |
| Sol, M | 1 |
| Gockeln, L | 1 |
| Sonneveld, R | 1 |
| van Kuppevelt, TH | 1 |
| de Graaf, M | 1 |
| van den Born, J | 1 |
| Kamps, JAAM | 1 |
| van Raalte, DH | 1 |
| van der Meer, RW | 1 |
| Lamb, HJ | 1 |
| Hillebrands, JL | 1 |
| Rabelink, TJ | 1 |
| Maciej-Hulme, ML | 1 |
| Krenning, G | 1 |
| Nijenhuis, T | 1 |
| van der Vlag, J | 1 |
| Carrasco, AG | 1 |
| Izquierdo-Lahuerta, A | 1 |
| Valverde, ÁM | 1 |
| Ni, L | 1 |
| Flores-Salguero, E | 1 |
| Coward, RJ | 1 |
| Medina-Gómez, G | 1 |
| Medić, B | 1 |
| Stojanović, M | 1 |
| Rovčanin, B | 1 |
| Kekić, D | 1 |
| Škodrić, SR | 1 |
| Jovanović, GB | 1 |
| Vujović, KS | 1 |
| Divac, N | 1 |
| Stojanović, R | 1 |
| Radenković, M | 1 |
| Prostran, M | 1 |
| Zhou, Y | 1 |
| Huang, Y | 1 |
| Ji, X | 1 |
| Wang, X | 1 |
| Shen, L | 1 |
| Wang, Y | 1 |
| Afzal, S | 1 |
| Abdul Sattar, M | 1 |
| Johns, EJ | 1 |
| Eseyin, OA | 1 |
| Sharma, A | 1 |
| Bourey, RE | 1 |
| Edwards, JC | 1 |
| Brink, DS | 1 |
| Albert, SG | 1 |
| Pane, B | 1 |
| Gazzola, V | 1 |
| Spinella, G | 1 |
| Bagnato, P | 1 |
| Grillo, F | 1 |
| Vellone, VG | 1 |
| Palombo, D | 1 |
| Shen, D | 1 |
| Li, H | 1 |
| Zhou, R | 1 |
| Liu, MJ | 1 |
| Yu, H | 1 |
| Wu, DF | 1 |
| Ali, RM | 1 |
| Al-Shorbagy, MY | 1 |
| Helmy, MW | 1 |
| El-Abhar, HS | 1 |
| Zhang, C | 2 |
| Zhang, Y | 2 |
| Liu, Y | 2 |
| Xu, G | 2 |
| Evans, PL | 1 |
| Prior, JA | 1 |
| Belcher, J | 1 |
| Hay, CA | 1 |
| Mallen, CD | 1 |
| Roddy, E | 1 |
| Sun, L | 1 |
| Xu, T | 1 |
| Chen, Y | 1 |
| Qu, W | 1 |
| Sun, D | 1 |
| Song, X | 1 |
| Yuan, Q | 1 |
| Yao, L | 1 |
| Németh, Á | 1 |
| Mózes, MM | 1 |
| Calvier, L | 1 |
| Hansmann, G | 1 |
| Kökény, G | 1 |
| Ochodnicky, P | 1 |
| Mesarosova, L | 1 |
| Cernecka, H | 1 |
| Klimas, J | 1 |
| Krenek, P | 1 |
| Goris, M | 1 |
| van Dokkum, RP | 1 |
| Henning, RH | 1 |
| Kyselovic, J | 1 |
| Abdel-Rahman, EM | 1 |
| Okusa, MD | 1 |
| El-Gowilly, SM | 1 |
| Helmy, MM | 1 |
| El-Gowelli, HM | 1 |
| Wang, J | 1 |
| Zhou, QD | 1 |
| Zhang, CH | 1 |
| Li, Q | 1 |
| Huang, S | 1 |
| Zhan, J | 1 |
| Wang, K | 1 |
| Liu, YY | 1 |
| Singh, AP | 1 |
| Singh, N | 1 |
| Bedi, PM | 1 |
| Tanaka, Y | 1 |
| Hasegawa, T | 1 |
| Chen, Z | 1 |
| Okita, Y | 1 |
| Okada, K | 1 |
| Yang, HC | 1 |
| Deleuze, S | 1 |
| Zuo, Y | 1 |
| Potthoff, SA | 1 |
| Ma, LJ | 1 |
| Fogo, AB | 1 |
| Al-Azzam, SI | 1 |
| Abdul-Razzak, KK | 1 |
| Jaradat, MW | 1 |
| Higashi, K | 1 |
| Oda, T | 1 |
| Kushiyama, T | 1 |
| Hyodo, T | 1 |
| Yamada, M | 1 |
| Suzuki, S | 1 |
| Sakurai, Y | 1 |
| Miura, S | 1 |
| Kumagai, H | 1 |
| Takemoto, M | 1 |
| Yokote, K | 1 |
| Kong, X | 1 |
| Zhang, DY | 1 |
| Wu, HB | 1 |
| Li, FX | 1 |
| Nagao, S | 1 |
| Yamaguchi, T | 1 |
| Mahmoud, MF | 1 |
| El Shazly, SM | 1 |
| Budde, K | 1 |
| Neumayer, HH | 1 |
| Fritsche, L | 1 |
| Sulowicz, W | 1 |
| Stompôr, T | 1 |
| Eckland, D | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Tomasoni, S | 1 |
| Campana, M | 1 |
| Corna, D | 1 |
| Zanchi, C | 1 |
| Gagliardini, E | 1 |
| Garofano, E | 1 |
| Rottoli, D | 1 |
| Ito, T | 1 |
| Remuzzi, G | 1 |
| Pereira, MG | 1 |
| Câmara, NO | 1 |
| Campaholle, G | 1 |
| Cenedeze, MA | 1 |
| de Paula Antunes Teixeira, V | 1 |
| dos Reis, MA | 1 |
| Pacheco-Silva, A | 1 |
| Li, X | 1 |
| Kimura, H | 1 |
| Hirota, K | 1 |
| Sugimoto, H | 1 |
| Kimura, N | 1 |
| Takahashi, N | 1 |
| Fujii, H | 1 |
| Yoshida, H | 1 |
| Namikoshi, T | 1 |
| Satoh, M | 1 |
| Tomita, N | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
5 reviews available for pioglitazone and Kidney Diseases
| Article | Year |
|---|---|
Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Chemoprevention; Diabetes Mellitus, Type 2; | 2020 |
Gender-specific risk factors for gout: a systematic review of cohort studies.
Topics: Age Factors; Animals; Body Size; Body Weight; Cohort Studies; Diabetes Complications; Diet; Diuretic | 2019 |
Effects of aging on renal function and regenerative capacity.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Aging; Animals; Cellular Senescence; Disease Models, A | 2014 |
[Prevention, treatment and management of inflammation in atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Biomarkers; C-Reactive Protein; Chronic D | 2011 |
PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
Topics: Animals; Cardiovascular Diseases; Cell Proliferation; Disease Models, Animal; Fibrosis; Hypoglycemic | 2012 |
1 trial available for pioglitazone and Kidney Diseases
| Article | Year |
|---|---|
The pharmacokinetics of pioglitazone in patients with impaired renal function.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Female; Half-Life; Humans; Hypoglyc | 2003 |
25 other studies available for pioglitazone and Kidney Diseases
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria.
Topics: Animals; Diabetes Mellitus, Type 2; Doxorubicin; Endothelial Cells; Humans; Kidney Diseases; Mice; P | 2023 |
The protective role of peroxisome proliferator-activated receptor gamma in lipotoxic podocytes.
Topics: Bexarotene; Humans; Kidney Diseases; Pioglitazone; Podocytes; PPAR gamma; Thiazolidinediones | 2023 |
Pioglitazone attenuates kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats.
Topics: Animals; Anti-Bacterial Agents; Catalase; Creatinine; Gentamicins; Hypoglycemic Agents; Kidney; Kidn | 2019 |
Renoprotective and haemodynamic effects of adiponectin and peroxisome proliferator-activated receptor agonist, pioglitazone, in renal vasculature of diabetic Spontaneously hypertensive rats.
Topics: Adiponectin; Animals; Diabetes Mellitus, Experimental; Hemodynamics; Hypertension; Hypoglycemic Agen | 2020 |
Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type lipodystrophy.
Topics: Adult; Female; Glomerulosclerosis, Focal Segmental; Humans; Hypoglycemic Agents; Kidney Diseases; Li | 2021 |
Inflammatory Response Modulation through a PPARγ Agonist during Surgically Induced Visceral Ischemia in an Animal Model.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Constriction; Cytoprotection; Disease Models, Animal; Infl | 2018 |
Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice.
Topics: Age Factors; Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Atherosclerosi | 2018 |
Role of Wnt4/β-catenin, Ang II/TGFβ, ACE2, NF-κB, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; beta Catenin; Cytoprotection; Disease Mode | 2018 |
Pioglitazone increases VEGFR3 expression and promotes activation of M2 macrophages via the peroxisome proliferator‑activated receptor γ.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Fibrosis; Gene Expression Regulation | 2019 |
Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation.
Topics: Animals; Cell Line; Fibrosis; HEK293 Cells; Humans; Kidney; Kidney Diseases; Male; Mice; Mice, Inbre | 2019 |
The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3.
Topics: Animals; Early Growth Response Protein 1; Fibrosis; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; | 2019 |
Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Disease Progression; Doxor | 2014 |
Pioglitazone ameliorates methotrexate-induced renal endothelial dysfunction via amending detrimental changes in some antioxidant parameters, systemic cytokines and Fas production.
Topics: Animals; Antioxidants; Cytokines; fas Receptor; Glutathione; Kidney; Kidney Diseases; Male; Malondia | 2015 |
Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice.
Topics: Animals; Chemokine CCL2; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Pioglita | 2016 |
Pioglitazone ameliorates renal ischemia reperfusion injury through NMDA receptor antagonism in rats.
Topics: Animals; Kidney Diseases; Male; Pioglitazone; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; R | 2016 |
Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy | 2009 |
The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.
Topics: Age Factors; Aging; Animals; Disease Progression; Kidney Diseases; Male; Pioglitazone; PPAR gamma; R | 2009 |
The nephroprotective effects of pioglitazone and glibenclamide against gentamicin-induced nephrotoxicity in rats: a comparative study.
Topics: Animals; Antioxidants; Creatinine; Disease Models, Animal; Gentamicins; Glyburide; Kidney Diseases; | 2010 |
Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl | 2010 |
Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blotting, Western; DNA Primers; Enz | 2011 |
Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines.
Topics: Animals; Benzhydryl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cisplatin; Epoxy Compounds; | 2013 |
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Gene Expression Regul | 2006 |
Pioglitazone limits cyclosporine nephrotoxicity in rats.
Topics: Animals; Arterioles; Blood Pressure; Body Weight; Creatinine; Cyclosporine; Drug Interactions; Gene | 2006 |
Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells.
Topics: Antioxidants; Cells, Cultured; Chemokine CCL2; Cyclic N-Oxides; Gene Expression Regulation; Humans; | 2007 |
Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy.
Topics: Animals; Endothelium, Vascular; Kidney Diseases; Kidney Glomerulus; Male; Metabolic Syndrome; NADPH | 2007 |